利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1454 条记录 (耗时 0.077 秒)

    Imaging agents for neural flux
    51.
    发明授权
    Imaging agents for neural flux 有权

    公开(公告)号：US10519160B2

    公开(公告)日：2019-12-31

    申请号：US15326890

    申请日：2015-07-17

    申请人： The General Hospital Corporation

    发明人： Genevieve Van de Bittner ,  Jacob M. Hooker

    IPC分类号： C07D473/40 ,  C07D473/16 ,  C07D487/04 ,  C07D473/34 ,  C07B59/00 ,  A61K51/04

    摘要： Provided herein are radiolabeled compounds useful for non-invasive imaging techniques. An exemplary radiolabeled compound provided herein is useful as a radiotracer for positron emission tomography. The present application also provides unlabeled compounds useful in methods of treating diseases of the central nervous system or disease of the peripheral nervous system. Methods for preparing radiolabeled compounds, preparing unlabeled compounds, and diagnostic methods using labeled or unlabeled compounds are also provided.

    INHIBITORS OF CYCLIN-DEPENDENT KINASES
    54.
    发明申请
    INHIBITORS OF CYCLIN-DEPENDENT KINASES 审中-公开

    公开(公告)号：US20190315747A9

    公开(公告)日：2019-10-17

    申请号：US15561729

    申请日：2016-03-25

    申请人： Dana-Farber Cancer Institute, Inc.

    发明人： Nathanael S. Gray ,  Tinghu Zhang ,  Nicholas Paul Kwiatkowski

    IPC分类号： C07D473/16 ,  C07D473/34 ,  C07D487/04 ,  A61P43/00

    摘要： The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.